BIOGEN INC. Accrued Income Taxes, Noncurrent
BIOGEN INC. (BIIB) had Accrued Income Taxes, Noncurrent of $174.20 million as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedIncomeTaxesNoncurrent · last filed 2026-04-29
- 2026-03-31: Accrued Income Taxes, Noncurrent $174.20M.
- 2025-12-31: Accrued Income Taxes, Noncurrent $166.40M.
- 2025-09-30: Accrued Income Taxes, Noncurrent $164.70M.
- 2025-06-30: Accrued Income Taxes, Noncurrent $165.10M.
| Period end | Accrued Income Taxes, Noncurrent |
|---|---|
| 2026-03-31 | $174.20M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $166.40M 10-Q · filed 2026-04-29 |
| 2025-09-30 | $164.70M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $165.10M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $162.10M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $156.70M 10-K · filed 2026-02-06 |
| 2024-09-30 | $162.00M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $191.70M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $411.00M 10-Q · filed 2024-04-24 |
| 2023-12-31 | $403.20M 10-K · filed 2025-02-12 |
| 2023-09-30 | $393.80M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $383.30M 10-Q · filed 2023-07-25 |
| 2023-03-31 | $552.50M 10-Q · filed 2023-04-25 |
| 2022-12-31 | $541.70M 10-K · filed 2024-02-14 |
| 2022-09-30 | $559.70M 10-Q · filed 2022-10-25 |
| 2022-06-30 | $499.60M 10-Q · filed 2022-07-20 |
| 2022-03-31 | $640.50M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $664.50M 10-K · filed 2023-02-15 |
| 2021-09-30 | $657.60M 10-Q · filed 2021-10-20 |
| 2021-06-30 | $652.70M 10-Q · filed 2021-07-22 |
| 2021-03-31 | $725.20M 10-Q · filed 2021-04-22 |
| 2020-12-31 | $709.90M 10-K · filed 2022-02-03 |
| 2020-09-30 | $729.30M 10-Q · filed 2020-10-21 |
| 2020-06-30 | $743.20M 10-Q · filed 2020-07-22 |
| 2020-03-31 | $801.30M 10-Q · filed 2020-04-23 |
| 2019-12-31 | $803.30M 10-K · filed 2021-02-03 |
| 2019-09-30 | $801.70M 10-Q · filed 2019-10-22 |
| 2019-06-30 | $801.50M 10-Q · filed 2019-07-24 |
| 2019-03-31 | $796.10M 10-Q · filed 2019-04-24 |
| 2018-12-31 | $791.40M 10-K · filed 2020-02-06 |
| 2018-09-30 | $786.90M 10-Q · filed 2018-10-23 |
| 2018-06-30 | $813.70M 10-Q · filed 2018-07-24 |
| 2017-12-31 | $979.80M 10-K · filed 2019-02-06 |
| 2014-12-31 | $142.20M 10-K · filed 2015-02-04 |
| 2014-09-30 | $187.70M 10-Q · filed 2014-10-22 |
| 2014-06-30 | $198.50M 10-Q · filed 2014-07-23 |
| 2013-12-31 | $177.10M 10-K · filed 2015-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |